Mold-Tek Packaging Ltd Q2 FY26 Earnings Analysis

Published 1 Jun 2026 | Industrial Products | Market Cap: ₹2.3K Cr

Price

703

Market Cap

₹2.3K Cr

P/E Ratio

32.3

Earnings Summary

- **Food & FMCG**: Targeting 20% volume growth from Q3 onwards; growth aided by Panipat plant starting food & FMCG production in August; 15-16% growth expected to continue; increased demand from FMCG clients including HUL, Marico, Nestle, GSK. - Mold-Tek Packaging expects volume growth of 12-15% for the full year, aiming for 43,000 to 45,000 tons.

📊 Revenue & Sales Performance

- **Food & FMCG**: Targeting 20% volume growth from Q3 onwards; growth aided by Panipat plant starting food & FMCG production in August; 15-16% growth expected to continue; increased demand from FMCG clients including HUL, Marico, Nestle, GSK. - **Paints**: Sustained volume around 5,400-5,500 tons per quarter expected; annual volume for paints could reach 21,000-22,000 tons; ABG is main growth driver. - **Pharma**: Revenue expected to grow from INR ~7.5 crores per quarter to over INR 10 crores by financial year-end; full-year target INR 35-36 crores; possible doubling/tripling next year; FDA approvals and new products expected to accelerate growth. - **Capacity**: Overall capacity to increase from ~63,000-64,000 tons to 70,000-72,000 tons by FY’26-end. - **Volume outlook**: Aim for 43,000-45,000 tons volume in the current financial year with 12-15% value growth and 18-20% revenue growth.

📈 Profitability & Margins

- Mold-Tek Packaging expects volume growth of 12-15% for the full year, aiming for 43,000 to 45,000 tons. - Focused growth in Paint (supported by ABG), Food & FMCG (targeting 20% volume growth Q3 onwards), and Pharma segments. - Pharma segment targets revenues of around INR 35-36 crores for the financial year, quadrupling from last year. - EBITDA margin improved to around 19.7% with 29% EBITDA per kg growth; net profit up by 35% in the latest quarter. - Per kg sales realization increased from INR198 to INR211, driven by higher value product mix including Pharma. - Expect consistent profitability and potential upside if Pharma and Food & FMCG growth accelerates. - Planned capacity expansions, including Panipat plant and pharma facilities, are likely to support future volume and profit growth.

🏗️ Capital Expenditure Plans

- Panipat plant capacity expansion: Starting production in August, expected to reach ~7,000 tons by end of financial year including food and Qpack segments. Additional 1,000 tons for food and 700-800 tons for paint/Qpack planned. - Pharma capacity expansion: New land acquired (2.5 acres adjacent to Sultanpur project) with plans for investments in injection molding machines and new product range. Brownfield expansion targeting INR100+ crore capacity possible. Production area expansion expected to begin end of calendar year, with new facilities operational by middle of next year. - Overall planned investment: INR80-90 crore this year specifically in pharma; previous 3 financial years saw INR130-140 crore invested. - Thin wall capacity in the North starting from August targeting 1,800-2,000 tons per annum by next financial year. - Panipat thin wall food products production starting August, adding high-value product lines. - Future pharma expansion phase planned on newly acquired adjacent land next financial year.

💰 Fundraising & Capital Structure

The transcript on page 17 and surrounding pages does not mention any current or planned fundraising through debt or equity. Key points related to financial plans are: - There are significant investments planned for capacity expansion, especially in pharma and Food & FMCG segments, with expected investments of INR 80-90 crores this year. - Expansion includes new land acquisition and facility construction, especially for pharma. - No explicit mention or discussion about raising funds through debt or equity in the current quarter or near future. - Focus appears to be on internal accruals and phased capacity scaling rather than external fundraising. Hence, based on the available information, there are no announced or imminent plans for new fundraising via debt or equity.

📋 Order Book & Pipeline

- The current order volumes indicate strong demand across segments, with an expected full-year volume target of 43,000 to 45,000 tons. - For the pharma segment, the run rate is improving. The quarterly revenue reached INR7.4–7.5 crores, with an anticipated increase to over INR10 crores per quarter by the financial year-end, potentially hitting around INR35–36 crores annually. - Food & FMCG segment is expected to grow significantly, aided by new product lines such as sweet packs at Panipat starting mid-August. - Paint segment orders remain robust, with 5,500 tons per quarter expected to sustain through the year, totaling around 21,000 to 22,000 tons annually. - The company is expanding capacity, aiming to increase total capacity from approximately 63,000–64,000 tons currently to about 70,000–72,000 tons by the end of the financial year, supporting larger order books.

Key Metrics

Frequently Asked Questions

What were Mold-Tek Packaging Ltd Q2 FY26 results?

- **Food & FMCG**: Targeting 20% volume growth from Q3 onwards; growth aided by Panipat plant starting food & FMCG production in August; 15-16% growth expected to continue; increased demand from FMCG clients including HUL, Marico, Nestle, GSK. - Mold-Tek Packaging expects volume growth of 12-15% for the full year, aiming for 43,000 to 45,000 tons.

What is Mold-Tek Packaging Ltd share price analysis?

Mold-Tek Packaging Ltd currently shows a neutral. The stock trades at a P/E of 32.3 with a market cap of ₹2,337. Investors should review the full earnings analysis for detailed insights.

Is Mold-Tek Packaging Ltd planning capital expenditure?

- Panipat plant capacity expansion: Starting production in August, expected to reach ~7,000 tons by end of financial year including food and Qpack segments.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.